Related references
Note: Only part of the references are listed.Cellular Heterogeneity and Molecular Evolution in Cancer
Vanessa Almendro et al.
ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 8 (2013)
Cancer heterogeneity: implications for targeted therapeutics
R. Fisher et al.
BRITISH JOURNAL OF CANCER (2013)
Detection and recovery of circulating colon cancer cells using a dielectrophoresis-based device: KRAS mutation status in pure CTCs
Francesco Fabbri et al.
CANCER LETTERS (2013)
Heterogeneity of Epidermal Growth Factor Receptor Status and Mutations of KRAS/PIK3CA in Circulating Tumor Cells of Patients with Colorectal Cancer
Christin Gasch et al.
CLINICAL CHEMISTRY (2013)
Circulating Tumor Cells: Liquid Biopsy of Cancer
Catherine Alix-Panabieres et al.
CLINICAL CHEMISTRY (2013)
KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue
Bianca Mostert et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Promising biomarkers for predicting the outcomes of patients with KRAS wild-type metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: A systematic review with meta-analysis
Zu-Yao Yang et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy
Emanuele Valtorta et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Cancer Cell Phenotypes, in Fifty Shades of Grey
Andriy Marusyk et al.
SCIENCE (2013)
Role of targeted agents in metastatic colorectal cancer
Hans Prenen et al.
TARGETED ONCOLOGY (2013)
Beyond KRAS mutation status: influence of KRAS copy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients
Leonie J. M. Mekenkamp et al.
BMC CANCER (2012)
Intratumor Heterogeneity: Evolution through Space and Time
Charles Swanton
CANCER RESEARCH (2012)
Review of biomarkers in colorectal cancer
K. F. Newton et al.
COLORECTAL DISEASE (2012)
Disseminated and circulating tumor cells in gastrointestinal oncology
F. C. Bidard et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2012)
Circulating Tumor Cell Count Is a Prognostic Factor in Metastatic Colorectal Cancer Patients Receiving First-Line Chemotherapy Plus Bevacizumab: A Spanish Cooperative Group for the Treatment of Digestive Tumors Study
Javier Sastre et al.
ONCOLOGIST (2012)
EMT Inducers Catalyze Malignant Transformation of Mammary Epithelial Cells and Drive Tumorigenesis towards Claudin-Low Tumors in Transgenic Mice
Anne-Pierre Morel et al.
PLOS GENETICS (2012)
Circulating tumor cells, colon cancer and bevacizumab: the meaning of zero
P. Gazzaniga et al.
ANNALS OF ONCOLOGY (2011)
KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients
N. Knijn et al.
BRITISH JOURNAL OF CANCER (2011)
Characterization of metastatic breast cancer patients with nondetectable circulating tumor cells
Michal Mego et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer
Wendy De Roock et al.
LANCET ONCOLOGY (2011)
Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents
J. Tol et al.
ANNALS OF ONCOLOGY (2010)
Prevalence and Heterogeneity of KRAS, BRAF, and PIK3CA Mutations in Primary Colorectal Adenocarcinomas and Their Corresponding Metastases
Stephan E. Baldus et al.
CLINICAL CANCER RESEARCH (2010)
Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab
Wendy De Roock et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Clinical Relevance of KRAS in Human Cancers
Sylwia Jancik et al.
JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY (2010)
Hypoxia Activates the K-Ras Proto-Oncogene to Stimulate Angiogenesis and Inhibit Apoptosis in Colon Cancer Cells
Min Zeng et al.
PLOS ONE (2010)
Significance of Circulating Tumor Cells Detected by the CellSearch System in Patients withMetastaticBreast Colorectal and Prostate Cancer
M. Craig Miller et al.
JOURNAL OF ONCOLOGY (2010)
Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer
S. J. Cohen et al.
ANNALS OF ONCOLOGY (2009)
Detection of KRAS Oncogene in Peripheral Blood as a Predictor of the Response to Cetuximab Plus Chemotherapy in Patients with Metastatic Colorectal Cancer
Li-Chen Yen et al.
CLINICAL CANCER RESEARCH (2009)
Implications for KRAS status and EGFR-targeted therapies in metastatic CRC
Nicola Normanno et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2009)
Multi-Determinants Analysis of Molecular Alterations for Predicting Clinical Benefit to EGFR-Targeted Monoclonal Antibodies in Colorectal Cancer
Andrea Sartore-Bianchi et al.
PLOS ONE (2009)
Transforming growth factor-beta signaling in epithelial-mesenchymal transition and progression of cancer
Kohei Miyazono
PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES (2009)
Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer
Steven J. Cohen et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Circulating tumour cells as a predictive factor for response to systemic chemotherapy in patients with advanced colorectal cancer
Silke Lankiewicz et al.
MOLECULAR ONCOLOGY (2008)
Share Paper
